Analysis of Revenues
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Cytokinetics Inc., income statement, revenues
US$ in thousands
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
- Revenue Trend
- The revenue demonstrated a generally increasing trend over the analyzed five-year period. Beginning at $31,501 thousand in 2018, it decreased to $26,868 thousand in 2019, marking the only year-over-year decline within the set. Subsequently, revenue experienced significant growth, reaching $55,828 thousand in 2020, which represents more than a doubling from the previous year.
- The upward trajectory continued in the subsequent years, with revenues attaining $70,428 thousand in 2021 and further increasing to $94,588 thousand in 2022. This pattern indicates strong revenue expansion, particularly from 2019 through 2022, reflecting a compound annual growth rate that suggests improving market performance or increased sales activities.
- Overall, the data reveals a recovery following the 2019 dip, with substantial growth in the later years, indicating a positive financial development in terms of revenue generation.